Kingswood Wealth Advisors LLC Reduces Stock Position in Gilead Sciences, Inc. $GILD

Kingswood Wealth Advisors LLC lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 72.1% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,979 shares of the biopharmaceutical company’s stock after selling 25,756 shares during the quarter. Kingswood Wealth Advisors LLC’s holdings in Gilead Sciences were worth $1,106,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences in the first quarter worth approximately $25,000. Activest Wealth Management raised its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the last quarter. Goodman Advisory Group LLC bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $29,000. Colonial Trust Advisors increased its position in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital increased its position in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 241 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,000 shares of company stock valued at $9,402,130. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 1.3%

NASDAQ:GILD opened at $118.25 on Thursday. Gilead Sciences, Inc. has a 1-year low of $84.17 and a 1-year high of $121.83. The company has a 50-day moving average of $114.48 and a 200 day moving average of $110.12. The firm has a market cap of $146.73 billion, a PE ratio of 23.56, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s payout ratio is currently 62.95%.

Analysts Set New Price Targets

GILD has been the subject of several recent analyst reports. Citigroup lifted their price objective on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Rothschild & Co Redburn boosted their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $117.67.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.